Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715587 | 0.78 | NPSR1 (0.47) | — | |
| SCHEMBL27951855 | 0.75 | SCN9A (0.50) | DHODH | |
| SCHEMBL19328529 | 0.73 | DHODH (0.48) | DHODH | |
| SCHEMBL432878 | 0.70 | CYP3A4 (0.52) | — | |
| SCHEMBL19328502 | 0.68 | PTGFR (0.51) | DHODH | |
| SCHEMBL19328500 | 0.66 | PTGFR (0.52) | DHODH | |
| SCHEMBL5598640 | 0.65 | CSF1R (0.48) | RORC | |
| SCHEMBL19328543 | 0.65 | PTGFR (0.51) | DHODH | |
| SCHEMBL148298 | 0.64 | PDE5A (0.65) | — | |
| SCHEMBL19328474 | 0.64 | PTGFR (0.52) | NAMPTDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | COMBINATORX, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20030207852-A1 | Treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2003-11-06 | — | — | US | disclosed |
| US-6593313-B2 | Administering to the vagina, vulvar area or urethra of the female a pharmaceutical formulation comprises a vasoactive agent selected from natural or synthetic prostaglandins, endothelial derived relaxation factors, hypotensive agents | VIVUS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1027057-A4 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | VIVUS INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6472434-B1 | VASOACTIVE AGENT IS ADMINISTERED TO THE VAGINA, VULVAR AREA OR URETHRA OF THE INDIVIDUAL UNDERGOING TREATMENT. SUITABLE VASOACTIVE AGENTS ARE VASODILATORS, INCLUDING NATURALLY OCCURRING PROSTAGLANDINS, SYNTHETIC PROSTAGLANDIN DERIVATIVES, | VIVUS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20010051656-A1 | Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | TNF, PYGM, IL6 | NAMPT 920/4885DHODH 3747/4885RORC 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.